Generate Biomedicines is trading 4.13% up at $15.90, outperforming a biotechnology sector down 4.24% on September 1, 2026, after H.C. Wainwright raised its price target to $30 from $25 while maintaining a Buy rating.

  • The analyst cited positive early GB-0895 asthma data.
  • Estimated approval probability increased to 80%.